[HTML][HTML] An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer

SV Lindskrog, F Prip, P Lamy, A Taber… - Nature …, 2021 - nature.com
The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized
by large biological heterogeneity with variable clinical outcomes. Here, we perform an …

Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance

N Klümper, DJ Ralser, J Ellinger, F Roghmann… - Clinical Cancer …, 2023 - AACR
Purpose: The antibody–drug conjugate enfortumab vedotin (EV) releases a cytotoxic agent
into tumor cells via binding to the membrane receptor NECTIN-4. EV was recently approved …

The tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes

C Pfannstiel, PL Strissel, KB Chiappinelli, D Sikic… - Cancer immunology …, 2019 - AACR
Muscle-invasive bladder cancer (MIBC) represents approximately two-thirds of invasive
urothelial bladder cancers (UBC) and has high morbidity and mortality. Men are over 3-fold …

[HTML][HTML] Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy …

M Eckstein, P Erben, MC Kriegmair, TS Worst… - European journal of …, 2019 - Elsevier
Abstract Background Recently, the Food and Drug Administration (FDA)/European
Medicines Agency (EMA) restricted first-line use of atezolizumab and pembrolizumab in …

[HTML][HTML] Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy …

M Eckstein, P Strissel, R Strick, V Weyerer… - … for Immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Assessment of the immune status of muscle-invasive bladder cancer (MIBC)
has previously shown to be prognostically relevant after treatment with curative intent. We …

Bladder Tumor Subtype Commitment Occurs in Carcinoma In Situ Driven by Key Signaling Pathways Including ECM Remodeling

A Wullweber, R Strick, F Lange, D Sikic, H Taubert… - Cancer research, 2021 - AACR
Basal and luminal subtypes of invasive bladder tumors have significant prognostic and
predictive impacts for patients. However, it remains unclear whether tumor subtype …

[HTML][HTML] Spatial immunephenotypes of distant metastases but not matched primary urothelial carcinomas predict response to immune checkpoint inhibition

F Erlmeier, N Klümper, L Landgraf, PL Strissel, R Strick… - European Urology, 2023 - Elsevier
Background The value of programmed cell death ligand-1 (PD-L1) to predict durable
responses to immune checkpoint inhibitors (ICIs) in metastatic urothelial carcinoma (mUC) is …

[HTML][HTML] CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based …

N Klümper, DJ Ralser, R Zarbl, K Schlack… - … for Immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background In metastatic clear cell renal cell carcinoma (ccRCC), different combination
therapies, each including anti-PD-1 immune checkpoint blockade (ICB), are applied as first …

[HTML][HTML] Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono …

V Weyerer, R Stoehr, S Bertz, F Lange… - World Journal of …, 2021 - Springer
Purpose Recently discovered molecular classifications for urothelial bladder cancer
appeared to be promising prognostic and predictive biomarkers. The present study was …

[HTML][HTML] mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological …

M Eckstein, RM Wirtz, M Gross-Weege… - International journal of …, 2018 - mdpi.com
Recently, muscle-invasive bladder cancer (MIBC) has been subclassified by gene
expression profiling, with a substantial impact on therapy response and patient outcome. We …